Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study
- 37 Downloads
Dried blot spot (DBS) analysis of drugs or clinical parameters offers many advantages. We investigated the feasibility of using DBS for analysis of anti-diabetic drugs concomitantly with the estimated creatinine clearance (Clcrea).
The cross-sectional study involved physicians in an enabling analysis with 70 diabetic patients and community pharmacists in a field investigation with 84 participants. All 154 DBS samples were analyzed for creatinine, metformin, and sitagliptin.
The diabetic patients revealed of a wide range of age (32–88 years), BMI values (19.8–54.7 kg/m2), and extent of polypharmacotherapy (1–21 drugs). A correlation factor to convert capillary blood creatinine from DBS into plasma concentrations was determined. Patients’ Clcrea ranged from 21.6–155.9 mL/min. The results indicated statistically significant correlations (p < 0.05) between the use of two or three particular drug classes (diuretics, NSAIDs, renin-angiotensin system blockers) and a decreased renal function. DBS concentrations of metformin ranged between 0.23–4.99 μg/mL. The estimated elimination half-life (t ½) of metformin was 11.9 h in patients with a ClCrea higher than 60 mL/min and 18.5 h for diabetics with lower ClCrea. Sitagliptin capillary blood concentrations ranged between 11.12–995.6 ng/mL. Calculated t ½ of sitagliptin were 8.4 h and 13.0 h in patients with a ClCrea above and below 60 mL/min, respectively.
DBS allow for the analysis of concentrations of predominantly renally eliminated drugs and community pharmacists can provide a valuable contribution to DBS sampling.
KeywordsMetformin Sitagliptin Creatinine Clinical study Dried blood spots Capillary blood
The authors would like to thank the patients and all 14 engaged community pharmacies for their participation in this study. The excellent technical assistance of Sabrina Rösel (office of Drs. Albert and Zieher) is gratefully acknowledged.
Compliance with ethical standards
Patients were recruited and enrolled in the study after written informed consent. The study was approved by the ethics committee of the Medical Faculty of the University of Würzburg (reference number 287/14) and the Freiburg Ethics Committee International (FEKI) and registered by ISRCTN (ISRCTN14518136).
Conflict of interests
The authors declare that they have no conflict of interest.
- 3.Martial LC, Aarnoutse RE, Schreuder MF, Henriet SS, Bruggemann RJ, Joore MA (2016) Cost evaluation of dried blood spot home sampling as compared to conventional sampling for therapeutic drug monitoring in children. PLoS One 11(12):e0167433. https://doi.org/10.1371/journal.pone.0167433 CrossRefGoogle Scholar
- 14.Piccoli GB, Grassi G, Cabiddu G, Nazha M, Roggero S, Capizzi I, De Pascale A, Priola AM, Di Vico C, Maxia S, Loi V, Asunis AM, Pani A, Veltri A (2015) Diabetic kidney disease: a syndrome rather than a single disease. Rev Diabet Stud 12(1–2):87–109. https://doi.org/10.1900/RDS.2015.12.87 CrossRefGoogle Scholar
- 19.Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S (2013) Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 346:e8525. https://doi.org/10.1136/bmj.e8525 CrossRefGoogle Scholar
- 27.Duong JK, Kroonen M, Kumar SS, Heerspink HL, Kirkpatrick CM, Graham GG, Williams KM, Day RO (2017) A dosing algorithm for metformin based on the relationships between exposure and renal clearance of metformin in patients with varying degrees of kidney function. Eur J Clin Pharmacol 73(8):981–990. https://doi.org/10.1007/s00228-017-2251-1 CrossRefGoogle Scholar
- 29.Chen X, Zhao Q, Zhang J, Liu T, Jiang J, Hu P (2016) An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. Int J Clin Pharmacol Ther 54(9):705–711. https://doi.org/10.5414/CP202646 CrossRefGoogle Scholar
- 30.Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA (2006) Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28(1):55–72. https://doi.org/10.1016/j.clinthera.2006.01.015 CrossRefGoogle Scholar